OncoMatch/Clinical Trials/NCT07776080
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Official title: A Clinical Study of Iparomlimab and Tuvonralimab Combined With Lenvatinib, Radiotherapy, and Hepatic Arterial Infusion Chemotherapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Is NCT07776080 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including Iparomlimab and Tuvonralimab (QL1706) and Lenvatinib for hcc - hepatocellular carcinoma.
Treatment: Iparomlimab and Tuvonralimab (QL1706) · Lenvatinib — The purpose of this study is to learn how well a combination of iparomlimab and tuvonralimab (QL1706), lenvatinib, radiotherapy, and hepatic arterial infusion chemotherapy (HAIC) works and how safe it is for people with hepatocellular carcinoma (HCC) that has grown into the portal vein, forming a portal vein tumor thrombus (PVTT). Participants will receive iparomlimab and tuvonralimab together with lenvatinib, radiotherapy directed at the portal vein tumor thrombus, and HAIC, which delivers chemotherapy directly through the hepatic artery. Researchers will evaluate how long the cancer remains controlled without getting worse, how much the tumors shrink, how long participants survive, and whether the treatment makes surgery possible for some participants. Treatment-related side effects will also be assessed. The study will also explore whether features in tumor tissue and blood are associated with treatment response and may help identify patients who are more likely to benefit from this treatment strategy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: targeted therapy
No prior systemic or local treatment directed at PVTT, including targeted therapy, immunotherapy, or systemic chemotherapy
Cannot have received: immunotherapy
No prior systemic or local treatment directed at PVTT, including targeted therapy, immunotherapy, or systemic chemotherapy
Cannot have received: systemic chemotherapy
No prior systemic or local treatment directed at PVTT, including targeted therapy, immunotherapy, or systemic chemotherapy
Cannot have received: radiotherapy
No prior systemic or local treatment directed at PVTT, including targeted therapy, immunotherapy, or systemic chemotherapy
Cannot have received: anticancer treatment
Prior targeted therapy, immunotherapy, radiotherapy, systemic chemotherapy, or other anticancer treatment
Lab requirements
Blood counts
WBC ≥3.0 × 10⁹/L; PLT ≥50 × 10⁹/L; hemoglobin ≥80 g/L
Kidney function
creatinine clearance ≥80 mL/min
Liver function
ALT ≤5 × ULN; AST ≤5 × ULN; total bilirubin ≤3 × ULN; albumin ≥28 g/L; Child-Pugh class A or B with a Child-Pugh score ≤7
Adequate organ function, including: WBC ≥3.0 × 10⁹/L; PLT ≥50 × 10⁹/L; hemoglobin ≥80 g/L; ALT ≤5 × ULN; AST ≤5 × ULN; total bilirubin ≤3 × ULN; albumin ≥28 g/L; and creatinine clearance ≥80 mL/min. Child-Pugh class A or B with a Child-Pugh score ≤7.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07776080 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages